Researchers sought to assess whether COVID-19 infection developed despite of vaccination among patients with multiple sclerosis or neuromyelitis optica spectrum disorder, using a French database of these patient populations.
Mothers, fathers, sisters, and brothers of children with one of four life-threatening conditions (LTCs) have higher rates of health care encounters, diagnoses, and medication prescriptions compared with family members of control children.
A recall of aromatherapy sprays connected with fatal cases of the rare tropical disease melioidosis has been expanded by the U.S. Centers for Disease Control and Prevention.
Use of genomic sequencing yields an increase in genomic diagnoses across a spectrum of rare diseases.
Peter Grayson, MD, of the NIH tells us the story behind the discovery of the new inflammatory syndrome, VEXAS, and the importance of research at a molecular level in rheumatology.
In this episode, Jonathan Miner, MD, discusses his contributions to the ultra-rare disease space in rheumatology.
The FDA has approved Ilaris for the treatment of active Still disease, including adult-onset Still disease.
Investigators characterized the effects and markers of response of omalizumab in normocomplementemic urticarial vasculitis.
A recent case report examined the adverse effects of alemtuzumab in a patient with relapsing remitting multiple sclerosis.
A protein epitope targeted by the antibody response in children with Kawasaki disease has been identified.
